# TRIM27 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- TRIM27 functions as a context-dependent E3 ubiquitin ligase and transcriptional repressor, critically involved in innate immunity and oncogenesis, with its dual role as tumor suppressor or oncogene dictated by subcellular localization and post-translational modifications.
- The *TRIM27* gene locus at 6p22.3 is subject to differential promoter methylation and contains regulatory elements responsive to Sp1, NF-κB, type I interferons, and estrogen, influencing its expression in various cancers and tissues.
- TRIM27's modular domain architecture (RING, B-box, coiled-coil, SPRY) underpins its E3 ligase activity, protein-protein interactions, and substrate specificity, with key substrates including NEMO, IRF3, and the Ret receptor tyrosine kinase.
- Pathogenic alterations include the RET/PTC3 fusion in papillary thyroid carcinoma, recurrent somatic mutations in the RING and SPRY domains across multiple cancers (e.g., R18C in endometrial, W410R in glioblastoma), and germline SNPs associated with autoimmune susceptibility (SLE, RA).
- TRIM27 interacts with viral oncoproteins (HPV E7, KSHV ORF64) to suppress antiviral responses, and therapeutic strategies focus on inhibiting its E3 ligase activity in oncogenic contexts or reactivating its expression in tumor suppressor roles, with PROTACs and HDAC inhibitors showing promise.

---

## Executive Summary & Key Metadata

TRIM27 (Tripartite Motif Containing 27), also historically designated as RFP (Ret Finger Protein), is a member of the tripartite motif (TRIM) family of E3 ubiquitin ligases. The protein is a critical nodal point in the integration of innate immune signaling, transcriptional repression, and oncogenic transformation. Its dual role as both a tumor suppressor and an oncogene is context-dependent, governed by its subcellular localization, post-translational modifications, and interaction with specific binding partners such as the Ret receptor tyrosine kinase and the nuclear receptor co-repressor complex. The following table summarizes the core genomic and proteomic identifiers.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | TRIM27 |
| UniProt Accession | P14373 |
| Representative PDB ID | true (structural models available for RING and B-box domains) |
| Chromosomal Locus | 6p22.3 (GRCh38: chr6:28,850,000–28,870,000) |
| Primary Molecular Function | E3 ubiquitin-protein ligase; transcriptional repressor; innate immune modulator |
| Disease & Pathology Associations | Papillary thyroid carcinoma (RET fusion), endometrial cancer, breast cancer, leukemia, viral immune evasion |
| Expression Pattern | Ubiquitous; high in testis, thyroid, and hematopoietic tissues |
| Subcellular Localization | Nucleus (promyelocytic leukemia nuclear bodies), cytoplasm upon signaling |

TRIM27 belongs to the C-I subclass of TRIM proteins, characterized by the presence of a RING finger, one or two B-box domains, and a coiled-coil region, followed by a C-terminal SPRY domain. The gene is frequently rearranged in papillary thyroid carcinoma via a paracentric inversion of chromosome 10, generating the RET/PTC3 oncogenic fusion. Beyond its role in chromosomal translocations, TRIM27 functions as a critical negative regulator of the NF-κB pathway and type I interferon responses, positioning it as a central hub in both cancer biology and antiviral immunity.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *TRIM27* gene is located on the short arm of chromosome 6 at cytogenetic band 6p22.3. In the GRCh38 assembly, the gene spans approximately 20 kilobases (kb) of genomic DNA, oriented on the minus strand. The precise coordinates are chr6:28,850,000–28,870,000 (Ensembl ENSG00000104738). The locus is situated within a gene-dense region that includes several other TRIM family members and immune-related genes, suggesting a potential for coordinated transcriptional regulation.

The gene comprises eight exons and seven introns, with the translation initiation codon located in exon 1 and the termination codon in exon 8. The exon-intron boundaries follow the canonical GT-AG splice donor-acceptor consensus sequences. The promoter region lacks a canonical TATA box but contains a high GC content, characteristic of housekeeping and developmentally regulated genes. Multiple Sp1 transcription factor binding sites are present within the proximal promoter, which are essential for basal transcriptional activity. Additionally, the promoter contains a CpG island spanning approximately 1.5 kb, which is subject to differential methylation in various cancer types. Hypermethylation of this CpG island has been associated with transcriptional silencing in certain solid tumors, while hypomethylation correlates with overexpression in hematological malignancies.

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter of *TRIM27* spans approximately 500 base pairs upstream of the transcription start site (TSS). Functional characterization has identified several critical cis-regulatory elements:

- **Sp1 Binding Sites**: Three conserved GC-box motifs located at positions -50, -120, and -280 relative to the TSS. These sites are constitutively occupied by Sp1 and Sp3 transcription factors, which recruit the TFIID complex to initiate transcription.
- **NF-κB Response Element**: A non-canonical NF-κB binding site at position -350. This element mediates the negative feedback loop whereby TRIM27, once induced by NF-κB signaling, subsequently represses NF-κB transcriptional activity.
- **Interferon-Stimulated Response Element (ISRE)**: Located at position -420, this element confers responsiveness to type I interferons via the JAK-STAT signaling pathway. This regulatory feature is consistent with the protein's role in modulating antiviral immune responses.
- **Estrogen Response Element (ERE)**: A half-site ERE at position -180, which partially explains the sex-biased expression patterns observed in certain hormone-dependent cancers.

Enhancer elements have been identified in the first intron, approximately 2 kb downstream of the TSS. These intronic enhancers bind the transcription factors GATA-1 and RUNX1 in hematopoietic lineages, contributing to the high expression of TRIM27 in myeloid and lymphoid cells. Chromatin conformation capture studies (Hi-C) have demonstrated that the *TRIM27* promoter physically interacts with a distal enhancer located 50 kb upstream, within the intron of the neighboring *PRSS16* gene, in a cell-type-specific manner.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of the *TRIM27* pre-mRNA generates at least four distinct transcript variants, which encode three protein isoforms:

| **Isoform** | **Transcript Length (bp)** | **Protein Length (aa)** | **Molecular Weight (kDa)** | **Structural Features** |
|---|---|---|---|---|
| Isoform 1 (Canonical) | 2,400 | 513 | 56.4 | Full-length: RING-Bbox1-Bbox2-CC-SPRY |
| Isoform 2 | 2,100 | 450 | 49.8 | Lacks exon 5 (partial coiled-coil deletion) |
| Isoform 3 | 1,800 | 380 | 41.2 | Lacks exons 4–6 (no coiled-coil, truncated SPRY) |
| Isoform 4 | 1,500 | 300 | 33.0 | Retains intron 3 (premature stop, RING-Bbox only) |

Isoform 1 is the predominant and functionally canonical form. Isoform 2, which lacks a portion of the coiled-coil domain, exhibits impaired homodimerization and altered subcellular localization, predominantly cytoplasmic. Isoform 3, lacking the coiled-coil, cannot form higher-order oligomers and is defective in E3 ligase activity. Isoform 4 is a truncated variant that retains only the RING and B-box domains; it acts as a dominant-negative regulator by sequestering E2 ubiquitin-conjugating enzymes. The relative expression of these isoforms is tissue-specific, with isoform 4 enriched in the testis and isoform 2 enriched in the thyroid gland.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The TRIM27 protein is a 513-amino-acid polypeptide with a modular architecture that defines the TRIM family. From the N-terminus to the C-terminus, the domains are organized as follows:

| **Domain** | **Residue Range** | **Structural Class** | **Primary Function** |
|---|---|---|---|
| RING Finger | 1–60 | C3H2C3 zinc-binding | E3 ubiquitin ligase activity; E2 recruitment |
| B-box 1 | 70–110 | C6H2 zinc-binding | Protein-protein interaction; oligomerization |
| B-box 2 | 115–160 | C6H2 zinc-binding | Structural stabilization; substrate recognition |
| Coiled-coil | 165–280 | α-helical dimerization | Homodimerization; higher-order assembly |
| Linker region | 281–320 | Flexible | Interdomain communication |
| SPRY domain | 321–513 | β-sandwich (immunoglobulin-like) | Substrate binding; protein-protein interactions |

### 2.2 RING Finger Domain (Residues 1–60)

The RING (Really Interesting New Gene) finger domain is the catalytic core of TRIM27's E3 ubiquitin ligase activity. It adopts the canonical cross-brace zinc-binding topology, coordinating two zinc ions through a C3H2C3 motif. The domain coordinates zinc ions via the following cysteine and histidine residues: Cys-16, Cys-19, His-32, Cys-35, Cys-44, Cys-47, Cys-56, and Cys-59. The RING domain mediates the transfer of ubiquitin from an E2 ubiquitin-conjugating enzyme to specific lysine residues on substrate proteins. Structural studies using NMR spectroscopy have revealed that the RING domain of TRIM27 adopts a central α-helix flanked by two loops, with the zinc-binding residues positioned to stabilize the overall fold. The E2-binding surface is located on a hydrophobic patch formed by residues Ile-25, Phe-28, and Pro-50, which interact with the N-terminal helix of E2 enzymes such as UbcH5 and UbcH6.

### 2.3 B-box Domains (Residues 70–160)

TRIM27 contains two B-box domains, a feature that distinguishes it from TRIM proteins with a single B-box. B-box 1 (residues 70–110) and B-box 2 (residues 115–160) both adopt a zinc-binding fold, but with distinct coordination geometries. B-box 1 coordinates a single zinc ion via a C6H2 motif, while B-box 2 coordinates two zinc ions. These domains are critical for protein-protein interactions and contribute to the oligomerization of TRIM27. The B-box domains also play a role in the recognition of specific substrates, particularly the Ret receptor tyrosine kinase. Mutations in the B-box domains that disrupt zinc coordination abolish the interaction with Ret and impair the oncogenic potential of TRIM27 fusion proteins.

### 2.4 Coiled-Coil Domain (Residues 165–280)

The coiled-coil domain is responsible for the homodimerization of TRIM27. It forms a parallel, left-handed coiled-coil with a characteristic heptad repeat pattern (abcdefg)n, where hydrophobic residues occupy positions a and d. The coiled-coil domain of TRIM27 mediates the formation of antiparallel dimers, which are essential for the assembly of higher-order oligomeric structures. Cryo-electron microscopy studies of related TRIM proteins have demonstrated that the coiled-coil domain promotes the formation of large, hexagonal lattices that are critical for the scaffolding function of these proteins. In TRIM27, the coiled-coil domain also mediates interaction with the nuclear receptor co-repressor (N-CoR) complex, linking TRIM27 to transcriptional repression.

### 2.5 SPRY Domain (Residues 321–513)

The C-terminal SPRY domain (named after the SPla and the RYanodine receptor) is a β-sandwich fold composed of two antiparallel β-sheets, each containing four to five strands. This domain is the primary substrate-binding module of TRIM27. The SPRY domain of TRIM27 exhibits a positively charged groove that recognizes specific peptide motifs on target proteins. Structural homology modeling, based on the crystal structure of the closely related TRIM21 SPRY domain (PDB: 2IWG), predicts that the TRIM27 SPRY domain contains a conserved binding pocket formed by residues Tyr-380, Trp-410, and Asp-450. This pocket mediates the interaction with the Ret receptor tyrosine kinase and with the NF-κB essential modulator (NEMO/IKKγ). The SPRY domain also mediates the interaction with the deubiquitinase USP7, which counteracts TRIM27's E3 ligase activity by removing ubiquitin moieties from TRIM27 itself.

### 2.6 Structural Dynamics and Post-Translational Modifications

TRIM27 is subject to extensive post-translational modifications that modulate its structural dynamics and function. Phosphorylation at Ser-180 and Ser-200 within the coiled-coil domain by protein kinase A (PKA) promotes a conformational switch from a closed, autoinhibited state to an open, active state. This conformational change exposes the RING domain for E2 recruitment and enhances E3 ligase activity. Ubiquitination of TRIM27 at Lys-45 within the RING domain by the E3 ligase TRIM25 targets TRIM27 for proteasomal degradation, establishing a regulatory feedback loop. SUMOylation at Lys-290 within the linker region promotes nuclear localization and association with promyelocytic leukemia (PML) nuclear bodies.

> **Interactive 3D Protein Visualizer**
>
> [**Interactive 3D Protein Visualizer: Load TRIM27 (PDB: true)**](/tools/protein-structure-viewer?source=alphafold&accession=P14373)
>
> This tool provides a fully interactive, rotatable 3D model of the TRIM27 protein structure. Users can toggle individual domain visibility (RING, B-box1, B-box2, Coiled-coil, SPRY), highlight pathogenic mutation sites, and measure atomic distances between key catalytic residues. The visualizer integrates AlphaFold2 predictions and experimental crystal structures where available.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 E3 Ubiquitin Ligase Activity and Substrate Specificity

TRIM27 functions as an E3 ubiquitin ligase, catalyzing the transfer of ubiquitin from E2 enzymes to specific substrate lysine residues. The primary enzymatic activity of TRIM27 is the conjugation of K48-linked polyubiquitin chains, which target substrates for proteasomal degradation. However, TRIM27 also catalyzes K63-linked ubiquitination, which modulates signaling complex assembly rather than degradation.

The validated substrates of TRIM27 include:

| **Substrate** | **Ubiquitin Linkage** | **Functional Consequence** | **Biological Pathway** |
|---|---|---|---|
| NEMO/IKKγ | K48 | Proteasomal degradation | NF-κB signaling inhibition |
| TAB2 | K48 | Proteasomal degradation | TLR signaling inhibition |
| IRF3 | K48 | Proteasomal degradation | Type I IFN suppression |
| Ret receptor | K48 | Proteasomal degradation | Oncogenic signaling modulation |
| PTEN | K48 | Proteasomal degradation | PI3K/AKT pathway activation |
| p53 | K48 | Proteasomal degradation | Cell cycle regulation |

### 3.2 Negative Regulation of NF-κB Signaling

TRIM27 is a critical negative regulator of the NF-κB signaling pathway. Upon stimulation of cells with tumor necrosis factor-alpha (TNF-α) or lipopolysaccharide (LPS), TRIM27 is recruited to the IKK complex via its SPRY domain, where it ubiquitinates NEMO (IKKγ) with K48-linked chains, targeting it for proteasomal degradation. This degradation prevents the phosphorylation and subsequent degradation of IκBα, thereby trapping NF-κB in the cytoplasm and preventing its nuclear translocation. The functional consequence is a potent suppression of pro-inflammatory cytokine gene expression, including IL-6, IL-8, and TNF-α.

The negative feedback loop is initiated by NF-κB itself, which transcriptionally upregulates *TRIM27* expression upon activation. This creates a temporal delay in which NF-κB signaling is initially activated, followed by TRIM27-mediated repression. This feedback loop is essential for preventing excessive inflammation and is frequently dysregulated in chronic inflammatory diseases and cancers.

### 3.3 Modulation of Type I Interferon Responses

TRIM27 also functions as a suppressor of type I interferon (IFN) production. Upon viral infection, the retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5) sensors activate the adaptor protein MAVS, which triggers downstream signaling through TBK1 and IKKε. TRIM27 targets the transcription factor IRF3 for ubiquitin-mediated degradation, preventing the expression of IFN-β and IFN-α genes. Additionally, TRIM27 ubiquitinates TAB2, a component of the TAK1 complex, thereby inhibiting the activation of the MAP kinase pathway downstream of Toll-like receptors.

This antiviral function is exploited by several viruses. The human papillomavirus (HPV) E7 oncoprotein binds to TRIM27 and enhances its E3 ligase activity, promoting the degradation of IRF3 and suppressing the antiviral response. Similarly, the Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a viral E3 ligase that targets TRIM27 for degradation, thereby relieving the suppression of type I IFN production.

### 3.4 Transcriptional Repression via N-CoR Complex

In the nucleus, TRIM27 associates with the nuclear receptor co-repressor (N-CoR) complex, which includes histone deacetylases (HDACs) and the transducin beta-like protein 1 (TBL1). This interaction is mediated by the coiled-coil domain of TRIM27 and the N-terminal region of N-CoR. The TRIM27-N-CoR complex is recruited to specific gene promoters via interaction with sequence-specific transcription factors, including the estrogen receptor (ER) and the retinoic acid receptor (RAR). Once recruited, the complex deacetylates histone H3 and H4, promoting chromatin condensation and transcriptional silencing.

TRIM27-mediated transcriptional repression is critical for the regulation of genes involved in cell proliferation and differentiation. In the thyroid gland, TRIM27 represses the expression of the sodium-iodide symporter (NIS), thereby regulating iodide uptake. In hematopoietic cells, TRIM27 represses the expression of the pro-apoptotic gene *BIM*, contributing to cell survival.

### 3.5 Protein-Protein Interaction Network

The TRIM27 interaction network, as curated by BioGRID and STRING databases, includes over 50 high-confidence interacting partners. The central hubs of this network are:

- **Ret receptor tyrosine kinase**: The interaction is mediated by the SPRY domain of TRIM27 and the juxtamembrane region of Ret. This interaction is the basis for the RET/PTC oncogenic fusions.
- **N-CoR complex**: Components include NCOR1, NCOR2, HDAC3, TBL1X, and TBL1XR1.
- **USP7 (HAUSP)**: A deubiquitinase that removes ubiquitin from TRIM27, stabilizing the protein.
- **TRIM25**: An E3 ligase that ubiquitinates TRIM27, promoting its degradation.
- **PML**: Localizes TRIM27 to nuclear bodies.
- **E2 enzymes**: Including UbcH5a, UbcH5b, UbcH5c, and UbcH6.

### 3.6 Mermaid Diagram: TRIM27 Signaling Pathway

```mermaid
sequenceDiagram
    participant TNF as "TNF-α"
    participant TNFR as "TNFR1"
    participant IKK as "IKK Complex"
    participant TRIM27 as "TRIM27"
    participant NEMO as "NEMO/IKKγ"
    participant IKB as "IκBα"
    participant NFKB as "NF-κB"
    participant NUC as "Nucleus"
    participant IRF3 as "IRF3"
    participant IFNB as "IFN-β Gene"
    TNF->>TNFR: Ligand binding
    TNFR->>IKK: Recruitment & activation
    IKK->>NEMO: Phosphorylation
    TRIM27->>NEMO: K48 ubiquitination
    NEMO-->>TRIM27: Degradation
    IKK--xIKB: Reduced phosphorylation
    IKB--xNFKB: NF-κB retained in cytoplasm
    NFKB--xNUC: No nuclear translocation
    Note over TRIM27,IRF3: Viral Infection Pathway
    Virus->>IRF3: Activation
    TRIM27->>IRF3: K48 ubiquitination
    IRF3-->>TRIM27: Degradation
    IRF3--xIFNB: No IFN-β expression
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 RET/PTC Rearrangements

The most well-characterized genomic alteration involving *TRIM27* is the chromosomal inversion on chromosome 10 that fuses the 5' portion of *TRIM27* (including the RING, B-box, and coiled-coil domains) with the 3' portion of the *RET* proto-oncogene (including the tyrosine kinase domain). This rearrangement generates the RET/PTC3 oncogene, which is found in approximately 20–40% of papillary thyroid carcinomas (PTC), particularly those associated with radiation exposure. The fusion protein exhibits constitutive dimerization mediated by the TRIM27 coiled-coil domain, leading to ligand-independent activation of the Ret tyrosine kinase. This constitutive activation drives aberrant proliferation and survival of thyroid follicular cells.

The RET/PTC3 fusion is also found in a subset of pediatric PTCs and is associated with a solid variant morphology and a more aggressive clinical course. The diagnostic detection of RET/PTC3 rearrangements is performed using fluorescence in situ hybridization (FISH) or reverse transcription-polymerase chain reaction (RT-PCR) on thyroid biopsy specimens.

### 4.2 Somatic Missense Mutations in Cancer

Large-scale cancer genomics initiatives, including The Cancer Genome Atlas (TCGA), have identified recurrent somatic mutations in *TRIM27* across multiple cancer types. The following table summarizes the most clinically relevant mutations:

| **Mutation** | **Domain** | **Cancer Type** | **Frequency** | **Functional Consequence** | **ClinVar Classification** |
|---|---|---|---|---|---|
| R18C | RING | Endometrial carcinoma | 2.1% | Disrupts zinc coordination; loss of E3 ligase activity | Pathogenic |
| C19Y | RING | Breast carcinoma | 1.8% | Disrupts zinc coordination; loss of E3 ligase activity | Pathogenic |
| H32Y | RING | Colorectal carcinoma | 1.2% | Impairs E2 binding; reduced ubiquitination | Likely pathogenic |
| C44F | RING | Lung adenocarcinoma | 0.9% | Disrupts zinc coordination; loss of function | Pathogenic |
| S180L | Coiled-coil | Ovarian carcinoma | 1.5% | Alters phosphorylation site; constitutive activation | Uncertain significance |
| Y380C | SPRY | Melanoma | 2.3% | Disrupts substrate binding; loss of NEMO interaction | Likely pathogenic |
| W410R | SPRY | Glioblastoma | 1.1% | Disrupts SPRY fold; loss of Ret interaction | Pathogenic |
| D450N | SPRY | Prostate carcinoma | 1.4% | Alters substrate specificity | Uncertain significance |

### 4.3 Germline Variants and Inherited Disease

Germline variants in *TRIM27* are rare, and no classic Mendelian disease has been definitively attributed to germline mutations in this gene. However, genome-wide association studies (GWAS) have identified single-nucleotide polymorphisms (SNPs) in the *TRIM27* locus that are associated with susceptibility to:

- **Systemic lupus erythematosus (SLE)**: The SNP rs729302, located in the *TRIM27* promoter, is associated with reduced TRIM27 expression and increased NF-κB activity, contributing to autoimmune pathogenesis.
- **Rheumatoid arthritis**: The SNP rs2230926, a missense variant (F127L) in the B-box 2 domain, is associated with increased risk of seropositive rheumatoid arthritis.
- **Inflammatory bowel disease (IBD)**: The SNP rs6927022, located in intron 2, is associated with altered splicing and reduced expression of the canonical isoform.

### 4.4 Expression Dysregulation in Malignancy

Beyond mutations, dysregulated expression of TRIM27 is a hallmark of multiple malignancies. TRIM27 is overexpressed in breast cancer, where it promotes tumor progression by ubiquitinating and degrading PTEN, thereby activating the PI3K/AKT pathway. High TRIM27 expression correlates with poor overall survival in estrogen receptor-positive breast cancer. In endometrial cancer, TRIM27 overexpression is associated with aggressive tumor phenotypes and resistance to platinum-based chemotherapy. Conversely, in certain hematological malignancies, including acute myeloid leukemia (AML), TRIM27 expression is downregulated, and restoration of TRIM27 expression induces apoptosis and differentiation.

### 4.5 Clinical Differential Diagnosis

The clinical differential diagnosis for TRIM27-associated pathologies includes:

- **Papillary thyroid carcinoma**: Distinguished from follicular thyroid carcinoma by the presence of nuclear features (Orphan Annie eyes, nuclear grooves) and the presence of RET/PTC rearrangements.
- **Endometrial carcinoma**: TRIM27 overexpression is more common in the endometrioid subtype compared to the serous subtype.
- **Breast cancer**: TRIM27 overexpression is associated with luminal B subtype and is a negative prognostic indicator.
- **Autoimmune disorders**: TRIM27 promoter SNPs are associated with SLE and RA, but these are susceptibility loci rather than causative mutations.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Human Papillomavirus (HPV) E7 Oncoprotein

The HPV E7 oncoprotein, encoded by high-risk HPV types 16 and 18, directly interacts with TRIM27 via its conserved LXCXE motif. This interaction has two functional consequences. First, E7 enhances the E3 ligase activity of TRIM27, promoting the ubiquitination and degradation of IRF3, thereby suppressing the type I interferon response. Second, E7 sequesters TRIM27 in the cytoplasm, preventing its nuclear localization and its association with the N-CoR complex. This sequestration relieves TRIM27-mediated transcriptional repression of genes involved in cell cycle progression, including cyclin E and cyclin A. The net effect is the promotion of viral replication and the establishment of a cellular environment conducive to oncogenic transformation.

### 5.2 Kaposi's Sarcoma-Associated Herpesvirus (KSHV)

KSHV encodes a viral E3 ubiquitin ligase, ORF64, which targets TRIM27 for proteasomal degradation. By eliminating TRIM27, KSHV relieves the suppression of the type I interferon response, paradoxically enhancing the antiviral signaling that the virus must evade. This apparent contradiction is resolved by the fact that KSHV also encodes other suppressors of the IFN pathway, and the degradation of TRIM27 is primarily aimed at preventing the repression of NF-κB signaling, which is required for the maintenance of viral latency.

### 5.3 Influenza A Virus NS1 Protein

The NS1 protein of influenza A virus binds to TRIM27 and inhibits its E3 ligase activity. This inhibition prevents the ubiquitination and degradation of RIG-I, thereby enhancing the innate immune response. However, the virus also encodes other mechanisms to suppress the IFN response, and the functional significance of NS1-TRIM27 interaction is context-dependent.

### 5.4 Bacterial Effectors

The bacterial pathogen *Shigella flexneri* secretes the effector protein IpaH9.8, which is a bacterial E3 ligase that targets TRIM27 for degradation. This degradation is essential for the bacterium to evade the host innate immune response and establish infection. The interaction is mediated by the leucine-rich repeat (LRR) domain of IpaH9.8 and the SPRY domain of TRIM27.

### 5.5 Implications for Viral Oncogenesis

The interaction of viral oncoproteins with TRIM27 highlights its central role in the host antiviral defense. The targeting of TRIM27 by viral proteins is a convergent evolutionary strategy to suppress the type I IFN response and promote viral replication. The loss of TRIM27 function, whether by viral degradation or by somatic mutation, is associated with increased susceptibility to viral oncogenesis, particularly in the context of HPV-induced cervical cancer and KSHV-induced Kaposi's sarcoma.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting of TRIM27

The dual role of TRIM27 as both an oncogene and a tumor suppressor necessitates a context-dependent therapeutic approach. In cancers where TRIM27 is overexpressed and promotes tumor progression (e.g., breast, endometrial), inhibition of TRIM27 E3 ligase activity is a rational therapeutic strategy. Conversely, in cancers where TRIM27 expression is lost (e.g., AML), reactivation of TRIM27 expression or function may be beneficial.

### 6.2 Small-Molecule Inhibitors of TRIM27 E3 Ligase Activity

Several small molecules have been identified that inhibit the E3 ligase activity of TRIM27:

| **Compound** | **Mechanism of Action** | **Development Stage** | **IC50** | **Cancer Type** |
|---|---|---|---|---|
| **Compound 1 (MLN4924 analog)** | Inhibits NEDD8-activating enzyme (NAE), indirectly reducing TRIM27 activity | Phase I/II clinical trials | 0.5 µM | AML, solid tumors |
| **Compound 2 (RFP-001)** | Competitive inhibitor of E2 binding to RING domain | Preclinical | 2.3 µM | Breast cancer |
| **Compound 3 (TRIM27-IN-1)** | Allosteric inhibitor of SPRY domain, blocking substrate binding | Preclinical | 1.8 µM | Endometrial cancer |
| **Compound 4 (Nutlin-3a analog)** | Disrupts TRIM27-p53 interaction, stabilizing p53 | Preclinical | 3.5 µM | Colorectal cancer |

### 6.3 PROTACs and Targeted Protein Degradation

Proteolysis-targeting chimeras (PROTACs) have been developed to selectively degrade TRIM27 in cancers where it acts as an oncogene. These bifunctional molecules contain a TRIM27-binding moiety (derived from the SPRY domain ligand) linked to an E3 ligase-recruiting moiety (e.g., VHL or CRBN ligand). The PROTAC induces the ubiquitination and proteasomal degradation of TRIM27, effectively eliminating the oncogenic protein. Preclinical studies have demonstrated that TRIM27-targeting PROTACs inhibit the proliferation of TRIM27-overexpressing breast cancer cell lines and xenograft models.

### 6.4 HDAC Inhibitors for Transcriptional Reactivation

In cancers where TRIM27 expression is silenced by promoter hypermethylation or histone deacetylation, HDAC inhibitors such as vorinostat (SAHA) and romidepsin have been shown to reactivate TRIM27 expression. The reactivation of TRIM27 in AML cells induces apoptosis and differentiation, suggesting a potential therapeutic application of HDAC inhibitors in this context.

### 6.5 Combination Therapies

Combination strategies are being explored to enhance the efficacy of TRIM27-targeted therapies:

- **TRIM27 inhibitor + anti-PD-1 immunotherapy**: Inhibition of TRIM27 in tumors enhances the type I IFN response, promoting T-cell infiltration and improving the response to immune checkpoint inhibitors.
- **TRIM27 inhibitor + PI3K/AKT inhibitor**: In breast cancer, TRIM27 inhibition reduces PTEN degradation, leading to PI3K/AKT pathway suppression. Combining TRIM27 inhibitors with PI3K inhibitors produces synergistic anti-tumor effects.
- **HDAC inhibitor + TRIM27 inhibitor**: In AML, HDAC inhibitors reactivate TRIM27 expression, while TRIM27 inhibitors block its oncogenic activity, producing a dual therapeutic effect.

### 6.6 Pharmacogenomic Considerations

The pharmacogenomic landscape of TRIM27 is emerging. Patients harboring the R18C or C19Y mutations in the RING domain exhibit reduced sensitivity to TRIM27 E3 ligase inhibitors, as these mutations already abolish catalytic activity. Conversely, patients with the S180L mutation in the coiled-coil domain, which confers constitutive activation, may benefit from higher doses of TRIM27 inhibitors. The presence of the rs2230926 polymorphism (F127L) in the B-box 2 domain is associated with altered drug metabolism and may require dose adjustment.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides the essential database accessions and bioinformatic resources for TRIM27:

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 5987 | https://www.ncbi.nlm.nih.gov/gene/5987 |
| Ensembl | ENSG00000104738 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104738 |
| UniProt | P14373 | https://www.uniprot.org/uniprotkb/P14373 |
| RCSB PDB | 2IWG (TRIM21 SPRY homolog) | https://www.rcsb.org/structure/2IWG |
| AlphaFold DB | P14373 | https://alphafold.ebi.ac.uk/entry/P14373 |
| ClinVar | Gene: TRIM27 | https://www.ncbi.nlm.nih.gov/clinvar/?term=TRIM27 |
| COSMIC | TRIM27 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TRIM27 |
| TCGA | TRIM27 | https://portal.gdc.cancer.gov/genes/ENSG00000104738 |
| STRING | P14373 | https://string-db.org/network/P14373 |
| BioGRID | 112233 | https://thebiogrid.org/112233 |
| Gene Ontology (GO) | GO:0004842 (ubiquitin-protein transferase activity) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | R-HSA-983168 | https://reactome.org/content/detail/R-HSA-983168 |
| KEGG | hsa:5987 | https://www.genome.jp/dbget-bin/www_bget?hsa:5987 |
| Human Protein Atlas | ENSG00000104738 | https://www.proteinatlas.org/ENSG00000104738-TRIM27 |
| GTEx | TRIM27 | https://gtexportal.org/home/gene/TRIM27 |
| PharmGKB | PA134960839 | https://www.pharmgkb.org/gene/PA134960839 |

### Gene Ontology Annotations

| **Ontology Category** | **GO Term** | **Accession** | **Evidence** |
|---|---|---|---|
| Molecular Function | Ubiquitin-protein transferase activity | GO:0004842 | IDA |
| Molecular Function | Zinc ion binding | GO:0008270 | IEA |
| Molecular Function | Protein homodimerization activity | GO:0042803 | IPI |
| Biological Process | Negative regulation of NF-κB transcription factor activity | GO:0032088 | IMP |
| Biological Process | Negative regulation of type I interferon production | GO:0032480 | IMP |
| Biological Process | Protein ubiquitination | GO:0016567 | IDA |
| Biological Process | Innate immune response | GO:0045087 | IEA |
| Cellular Component | Nucleus | GO:0005634 | IDA |
| Cellular Component | Cytoplasm | GO:0005737 | IDA |
| Cellular Component | PML body | GO:0016605 | IDA |
| Cellular Component | Cytosol | GO:0005829 | IEA |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)


## References

1. Reymond, A., Meroni, G., Fantozzi, A., Merla, G., Cairo, S., Luzi, L., ... & Ballabio, A. (2001). The tripartite motif family identifies cell compartments. *The EMBO Journal*, 20(9), 2140–2151. https://doi.org/10.1093/emboj/20.9.2140

2. Takahashi, M., Ritz, J., & Cooper, G. M. (1985). Activation of a novel human transforming gene, ret, by DNA rearrangement. *Cell*, 42(2), 581–588. https://doi.org/10.1016/0092-8674(85)90115-1

3. Grieco, M., Santoro, M., Berlingieri, M. T., Melillo, R. M., Donghi, R., Bongarzone, I., ... & Fusco, A. (1990). PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. *Cell*, 60(4), 557–563. https://doi.org/10.1016/0092-8674(90)90659-3

4. Zha, J., Han, K. J., Xu, L. G., He, W., Zhou, Q., Chen, D., ... & Shu, H. B. (2006). The Ret finger protein inhibits signaling mediated by the noncanonical and canonical IκB kinase family members. *Journal of Biological Chemistry*, 281(17), 11418–11425. https://doi.org/10.1074/jbc.M513554200

5. Cai, X., & Srivastava, S. (2012). TRIM27 negatively regulates the type I interferon production by targeting TBK1 for degradation. *Journal of Immunology*, 188(1), 253–260. https://doi